[Value of a percutaneous estrogen solution in stopping lactation].
An open trial involving 121 women was carried out to compare the efficacy and safety of a percutaneous estrogen solution and of an anti-prolactin solution. The complete inhibition of the let-down of milk was slightly less frequently obtained with the Percutacrine Oestrogénique that with Parlodel. The efficacy of Percutacrine Oestrogénique was linked to two conditions of administration: administration soon after delivery and compliance with the dosage, which was less frequently achieved than with Parlodel. In contrast, the clinical safety of Percutacrine Oestrogénique was excellent, and significantly better than that of Parlodel, notably with regard to dizziness (p less than 0.001 for the first 5 days of treatment). The incidence of the depressive tendency commonly observed post-partum was lower in the group of women receiving Percutacrine Oestrogénique, and reached the level of significance after 10 days of treatment.
Fournier
S
S
Laboratoires Besins-Iscovesco, Paris.
Foucher
E
E
Faguer
B
B
Pathier
D
D
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D012996:Solutions
D004967:Estrogens; D012996:Solutions; D001971:Bromocriptine
Intérêt d'une solution oestrogénique percutanée pour le blocage de la lactation.